OCC chart, page-332

Revver,

"Existing products have inferior functionality and handling characteristics"

"Study results demonstrate CelGro® results in up to 26% better quality newly formed bone when compared to market leading comparative product."

"CelGro® is approved for use in Europe (CE Mark) in a variety of dental bone and soft tissue regeneration procedures and has demonstrated superior clinical performance for dental bone defect repair when compared to the market leading product. The EAO Annual Scientific Meeting provided Orthocell and its Key Opinion Leaders (KOLs) with an opportunity to present the successful CelGro® bone repair clinical data and have direct interaction with clinicians, distributors and potential partners. This represents a key milestone in Orthocell’s commercialisation strategy, leading to greater awareness and recognition of Orthocell’s superior collagen membrane for dental bone defect repair."

"Professor Ming Hao Zheng, from the University of Western Australia and Orthocell’s Chief Scientific Officer presented the successful CelGro® bone repair study results highlighting the membranes superior handling qualities and bone repair outcomes when used for Guided Bone Regeneration (GBR) treatment to preserve or restore bone volume required for successful functional and aesthetic outcomes in dental implant procedures."

ASX announcement 18/10/2018.